Title

Murine CNS and bone marrow distribution of the aurora A kinase inhibitor alisertib: pharmacokinetics and exposure at the sites of efficacy and toxicity

Authors

Ju-Hee Oh1*, Erica A. Power2,3*, Wenjuan Zhang1, David J. Daniels2, William F. Elmquist1

Affiliation

1Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, U.S.A.

2Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, U.S.A.

3Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA

* Oh and Power equally contributed to the manuscript.
Running title: CNS and bone marrow distribution of alisertib

Corresponding author

Ju-Hee Oh

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 308 Harvard ST SE, Minneapolis MN 55455; Phone: (612) 625-2446; e-mail: oh000074@umn.edu

William F. Elmquist

Distinguished Professor, Department of Pharmaceutics, University of Minnesota, 308 Harvard ST SE, Minneapolis MN 55455; Phone: (612) 625-0097; fax: 612-626-2125; e-mail: elmqu011@umn.edu

Number of text pages: 22

Number of tables: 5

Number of figures: 8

Number of references: 59

Number of words in abstract: 247

Number of words in introduction (excluding text citations): 719

Number of words in discussion (excluding text citations): 2069
Abbreviations

AUC, area under the curve; BBB, blood-brain barrier; Bcrp, breast cancer resistance protein; Bcrp1, gene encoding the murine breast cancer resistance protein; CED, convection-enhanced delivery; CNS, central nervous system; Kp, tissue-to-plasma partition coefficient; Kp,uu, unbound tissue-to-plasma partition coefficient; LC-MS/MS, liquid chromatography-tandem mass spectrometry; Mdr1, gene encoding the murine P-glycoprotein; NCA, non-compartmental analysis; P-gp, P-glycoprotein

Recommended section: Metabolism, Transport, and Pharmacogenomics
Abstract

Important challenges in developing drugs that target central nervous system (CNS) tumors include overcoming barriers for CNS delivery and reducing systemic side effects. Alisertib, an aurora A kinase inhibitor, has been examined for treatment of several CNS tumors in preclinical and clinical studies. In this study, we investigated the distribution of alisertib into the CNS, the site of efficacy for brain tumors, and into the bone marrow, the site of dose-limiting toxicity leading to myelosuppression. Mechanisms influencing site-specific distribution, such as active transport mediated by the efflux proteins, p-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp), were examined. Alisertib exposure to the brain in wild-type mice was less than 1% of that in the plasma, and was evenly distributed throughout various brain regions and the spinal cord. Studies using transporter knockout mice and pharmacological inhibition show that alisertib CNS distribution is influenced by P-gp, but not Bcrp. Conversely, upon systemic administration, alisertib distribution to the bone marrow occurred rapidly, was not significantly limited by efflux transporters, and reached higher concentrations than in the CNS. This study demonstrates that, given an equivalent distributional driving force exposure in plasma, the exposure of alisertib in the brain is significantly less than that in the bone marrow, suggesting that targeted delivery may be necessary to guarantee therapeutic efficacy with minimal risk for adverse events. Therefore, these data suggest that, to improve the therapeutic index when using alisertib for brain tumors, a localized regional delivery, such as convection-enhanced delivery, may be warranted.
Significance Statement

The CNS penetration of alisertib is limited with uniform distribution in various regions of the brain and P-gp efflux is an important mechanism limiting that CNS distribution. Alisertib rapidly distributes into the bone marrow, a site of toxicity, with a greater exposure than in the CNS, a possible site of efficacy. These results suggest a need to design localized delivery strategies to improve the CNS exposure of alisertib and limit systemic toxicities in the treatment of brain tumors.
Introduction

A prerequisite for the treatment of central nervous system (CNS) diseases such as brain tumors is adequate delivery of a drug into target tissues and to maintain the drug concentration above a minimum therapeutic concentration. This fundamental step, however, acts as a bottleneck on the drug development process and consequently, insufficient efficacy attributed to poor drug distribution into the CNS is considered as a major cause of development failure. An major obstacle of drug penetration into the CNS is the blood-brain barrier (BBB) that impedes influx of endogenous and exogenous compounds into the brain by both physical barriers (e.g., tight junction proteins between brain endothelial cells) and biochemical barriers (e.g., drug efflux transporters) (Banks, 2016; Sarkaria et al., 2018). The constitutive function of the BBB is to protect the brain and to maintain homeostasis of the brain microenvironment. However, with respect to CNS diseases such as intracranial tumors, the BBB is the object to surmount for achieving a therapeutic drug concentration in lesions (Weiss et al., 2009). Drug distribution into the target tissues could be improved by dose manipulation, but it is highly likely to accompany an increase in systemic or untargeted exposure to the drug, leading to unintended adverse events. Indeed, one of the reasons for the withdrawal of drug candidates from the drug development process is unintended or severe adverse events. Effective treatment of CNS diseases requires by both sides, minimizing side effects as well as maximizing therapeutic effects.

Alisertib is a selective aurora A kinase inhibitor undergoing clinical trials for several tumors in monotherapy or in combination therapy (Otto and Sicinski, 2017; Mou et al., 2021). Aurora A kinase is a serine/threonine kinase that is a therapeutic target in oncology since it has an essential role in the cell division process, such as spindle assembly and chromosome segregation during mitosis, and is overexpressed in solid and hematological malignancies. Aurora A kinase inhibitors such as alisertib block cell proliferation at the G2/M phase and, consequently, induce cell cycle arrest followed by apoptosis (Niu et al., 2015). Although alisertib has not yet been approved by FDA for any indications, reports showing its potential for treatment of a variety of cancers, including brain tumors, have been
accumulating. For instance, it has been observed that the expression of aurora A kinase is greater in higher grade gliomas (Lehman et al., 2012). In addition, alisertib monotherapy prolongs survival of orthotopic xenografts of patient-derived glioblastoma resistant to bevacizumab (Kurokawa et al., 2017). Interestingly, alisertib affects expression of aurora kinase-related genes which are abnormally expressed in the patient-derived H3K27M cell lines. H3K27M mutation is a somatic mutation occurring in 78% of diffuse midline gliomas that have lysine 27 of histone H3 replaced by methionine. Alisertib also elicits therapeutic benefits in H3K27M tumors in animal models (Wu et al., 2012; Zhang et al., 2018). Currently, a phase 2 clinical trial of alisertib as a single agent and in combination therapy against atypical teratoid rhabdoid tumors is underway (NCT02114229).

Even with potential anticancer efficacy against intracranial tumors, it is important to determine the BBB penetrability and brain distribution of alisertib. A few previous reports indicate that alisertib can cross the BBB to present measurable brain concentrations, but the brain-to-plasma partition coefficient is low. This may be in part due to unfavorable physicochemical properties for brain penetration (Agarwal, Sane, et al., 2011; Hill et al., 2015; Sells et al., 2015; Kogiso et al., 2018). Moreover, a major cause limiting CNS distribution of anticancer agents is active efflux transport mediated by p-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp). These transporters, however, may still constrain entry of therapeutics into the tumor cells regardless of the leakiness of the BBB and as such attenuate efficacy. Indeed, tumors are guarded by “two layers of efflux transport protection” (Agarwal, Sane, et al., 2011) which consists of efflux pumps on brain endothelial cells and tumor cells (de Gooijer et al., 2021; Griffith et al., 2021). Since efflux transporters can impact drug delivery into brain tumors even when the BBB is leaky, understanding the impact of efflux is essential to achieve effective concentrations within both the tumor core and infiltrative regions.

In this study, we investigated the distribution of alisertib into the CNS (i.e., brain and spinal cord) and the bone marrow, sites of efficacy and toxicity, respectively. We also characterized the role of P-gp and Bcrp in CNS and bone marrow distribution of alisertib using a transgenic mouse lacking efflux transporters.
These studies conducted in mice suggest that following systemic administration alisertib exposure at the site of efficacy, the CNS, is limited when compared to the exposure at a site of toxicity, the bone marrow, indicating that localized delivery to tumor sites in the brain may be warranted (Figure 8).
Materials and Methods

Chemicals and reagents

Alisertib (4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid, purity 99.46%) and MLN8054 (4-[[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid, purity 97.90%) were purchased from Selleck Chemicals (Houston, TX). Elacridar (N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide, purity 98%) was obtained from Toronto Research Chemicals (Toronto, ON, Canada). Captisol® was kindly donated from CyDex Pharmaceutical, Inc. (San Diego, CA). All other chemicals were of HPLC-grade or analytical grade and purchased from Thermo Fisher Scientific (Waltham, WA) and MilliporeSigma (St. Louis, MO).

Animals

Pharmacokinetic studies were conducted using an equal number of male and female Friend Leukemia Virus strain B wild-type, Mdr1a/b−/− (P-gp knockout), Bcrp1−/− (Bcrp knockout), and Mdr1a/b−/−Bcrp1−/− (triple knockout of P-gp and Bcrp) mice at the age of 8 – 16 weeks (Taconic Biosciences, Inc., Germantown, NY). Animals were maintained in a facility accredited by American Association for the Accreditation of Laboratory Animal Care at the Academic Health Center of the University of Minnesota and were housed under a 12 light/12 dark cycle with free access to food and water. Genotyping was regularly conducted to validate gene expression by tail biopsy (Transnetyx, Cordova, TN) since the gene expression and deletion had been confirmed in wild-type and transgenic mice using proteomic analysis (Agarwal et al., 2012). All animal experiments were approved by the University of Minnesota Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals established by the U.S. National Institutes of Health.

Protein binding in mouse plasma, brain, and spinal cord
Free fraction of alisertib was determined in mouse plasma, brain, and spinal cord by using a rapid equilibrium dialysis device with a 8-kDa molecular weight cutoff cellulose membrane according to the manufacturer’s protocol (Thermo Fisher Scientific). Before conducting the protein binding assay, brain and spinal cord from mice were homogenized in 3 volume (w/v) of phosphate-buffered saline. Homogenization was performed using a mechanical homogenizer (THB-01, Omni International, Inc., Kennesaw, GA) at the medium speed setting for 30 seconds. After adjusting pH of blank plasma, brain homogenate, and spinal cord homogenate (i.e., alisertib-free matrix) to 7.4, alisertib solutions in dimethylsulfoxide (DMSO) were added to each blank matrix to a final concentration of 2 and 10 µM containing 0.5% of DMSO. The total drug concentrations were chosen considering the drug concentrations in plasma, brain, and spinal cord in mice after intravenous administration of 5 mg/kg of alisertib. The tissue matrix containing alisertib was added to the insert in the donor chamber, and then phosphate-buffered saline containing 0.5% DMSO was added to the corresponding receiver chamber. The device was covered with sealing tape and incubated at 37°C with shaking at 600 rpm. After 24 hours, samples were collected from both chambers and were kept at -80°C until LC-MS/MS analysis. Unbound fraction of alisertib in plasma was calculated by the ratio of drug concentration in the receiver chamber to the drug concentration in the donor chamber. Unbound fraction of alisertib in brain and spinal cord was calculated using the following equation as reported previously (Kalvass and Maurer, 2002):

\[
\text{Unbound fraction} (f_u) = \frac{1/D}{\left(\frac{1}{f_{u,\text{diluted}}} - 1\right) + \frac{1}{D}}
\]

(Equation 1)

where D is the dilution factor, in this case 4, and \(f_{u,\text{diluted}}\) is the ratio of the drug concentration in the receiver chamber to the drug concentration in the donor chamber.

**Determination of blood-to-plasma ratio**

Blood-to-plasma ratio of alisertib was determined as previously reported with the following modification (Wen et al., 2010). Briefly, alisertib solution in DMSO was spiked into whole blood and plasma to a final
concentration of 1 and 10 µM. The drug concentrations were decided considering the plasma concentration of alisertib in mice after intravenous administration of 5 mg/kg of alisertib. Spiked blood and plasma were then incubated at 37°C for 1 hour with shaking at 50 rpm. Whole blood was then centrifuged at 14,000 rpm for 5 min at 4 °C to separate test plasma. Plasma incubated with alisertib was used as the control plasma and plasma separated from whole blood after incubation with alisertib was used as the test plasma. Blood-to-plasma ratio was calculated by the ratio of the alisertib concentration in the control plasma to the alisertib concentration in the test plasma.

**Pharmacokinetic study in wild-type and transporter-knockout mice**

Dosing solution was solubilized in 10% Captisol® containing 0.7 – 0.8% (v/v) 1N NaOH to a final concentration of 1 mg/mL of alisertib. The pH of the dosing solution was checked with a pH indicator strip before administration to assure the pH was close to physiological. A single intravenous dose of 5 mg/kg alisertib was administered to each genotype through the tail vein followed by serial euthanasia from 5 minutes to 24 hours for wild-type and *Mdr1a/b<sup>−/−</sup>Bcrp1<sup>−/−</sup>* mice, and at 1 hour post-dose for *Mdr1a/b<sup>−/−</sup>* and *Bcrp1<sup>−/−</sup>* mice using CO₂ gas (n=4, 2 males and 2 females per each time point). Blood was collected by cardiac puncture using a heparinized syringe followed by centrifugation at 14000 rpm for 5 minutes at 4°C to separate plasma. The brain was surgically removed from the skull and rinsed with saline. Following removal of superficial meninges by blotting with Kimwipes, the brain was divided into 6-anatomical regions including the cortex, cerebellum, hypothalamus + thalamus, midbrain, pons, and medulla. The spinal cord was harvested by hydraulic extrusion from distal end of a spinal column using a syringe equipped with a 15G needle (Richner *et al.*, 2017). Bone marrow was isolated by centrifugation of femurs and tibias from hind limbs as reported previously (Amend *et al.*, 2016). Plasma and tissue specimens were stored at -80°C until analysis using LC-MS/MS.

**Co-administration of alisertib with elacridar**
Wild-type and Mdr1a/b<sup>-/-</sup>Bcrp1<sup>-/-</sup> mice were randomly divided into two groups. One group, the vehicle-treated group, was dosed 10 mL/kg of elacridar vehicle and the other group, the elacridar-treated group, was dosed 10 mg/kg of elacridar microemulsion in Cremophore EL, Carbitol, and Captex in 6:3:1 ratio. Alisertib was intravenously administered to both groups at 5 mg/kg immediately after intraperitoneal injection of elacridar vehicle or elacridar microemulsion. Dosing regimen of elacridar was determined based on plasma concentration and plasma protein binding of elacridar (Kallem et al., 2012; Sane, Mittapalli, et al., 2013). Plasma, whole brain, and spinal cord were collected after 0.25 and 1 hour of administration of alisertib, and then stored at -80°C until LC-MS/MS analysis.

**LC-MS/MS analysis to measure plasma and tissue concentration**

Brain and spinal cord were homogenized in 2 tissue volumes of 5% bovine serum albumin solution (w/v) prior to extraction. Bone marrow was homogenized in 3 tissue volumes of 5% bovine serum albumin solution (w/v) and then diluted in a mixture of blank plasma and 5% bovine serum albumin (1:3, v/v). Fifty microliters of plasma and tissue homogenate were spiked with 5 ng of MLN8054 as an internal standard followed by adding 500 µL of ethyl acetate. The mixture was vortex mixed for 5 minutes at room temperature, and then centrifuged at 14000 rpm for 5 minutes at 4°C. After freezing at -80°C for 20 minutes, the organic layer on the top was decanted into a microcentrifuge tube and evaporated under nitrogen gas. Dried residue was reconstituted in 100 µL and 50 µL of a mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (30:70, v/v) for plasma and tissues, respectively, and then centrifuged at 14000 rpm for 5 minutes at 4°C. Supernatant was transferred into a glass vial insert and 5 µL of aliquot was injected into Synergi™ Polar-RP column (75 × 2 mm, 4 µm, 80 Å; Phenomenex, Torrance, CA) connected to an Agilent 1200 series HPLC system (Agilent Technologies, Santa Clara, CA). The column temperature was maintained at 30°C during analysis. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). A gradient elution was employed as follows at a flow rate of 0.5 mL/min: solvent B was held at 70% for 1 minute, linearly ramped from 70% to 100% in 0.25 minutes, held at 100% for 2 minutes, and brought back down to 70%
for 3.5 minutes. A TSQ Quantum Classic and a TSQ Vantage triple stage quadrupole mass spectrometer (Thermo Finnigan, San Jose, CA) equipped with an electrospray ionization source were used to measure plasma concentration and tissue concentration, respectively. The analysis was performed using single reaction monitoring system with the transitions of $m/z$ 519.1 $>$ 328.1 and $m/z$ 477.1 $>$ 316.0 for alisertib and MLN8054, respectively, in positive electrospray ionization mode. The limit of quantifications were 1 ng/mL, 0.2 ng/mL, and 0.1 ng/mL for plasma, brain and spinal cord homogenate, and bone marrow homogenate, respectively. The precision (coefficient of variation less than 15%) and accuracy (relative error less than 15%) were both within acceptable limits.

**Correction of the brain concentration by subtracting the drug amount in residual brain blood**

The alisertib concentration measured in brain homogenate is derived from the concentration of alisertib in the brain tissue and the residual blood in that tissue. This requires that the brain homogenate concentrations be corrected by subtracting the alisertib amount in the cerebral blood from that in the brain homogenate. This is accomplished using the blood-to-plasma ratio and hematocrit.

By definition, a blood-to-plasma ratio in the brain specimen is as follows:

$$R_b = \frac{\text{Drug concentration in blood}}{\text{Drug concentration in plasma}} = \frac{A_{b,\text{brain}}}{A_{p,\text{brain}}}/\frac{V_{b,\text{brain}}}{V_{p,\text{brain}}}$$

(Equation 2)

where $R_b$, $A_{b,\text{brain}}$, $V_{b,\text{brain}}$, $A_{p,\text{brain}}$, and $V_{p,\text{brain}}$ are the blood-to-plasma ratio, the drug amount in cerebral blood, the volume of blood in the brain, the drug amount in cerebral plasma, and the volume of plasma in the brain. Given 1.4% of plasma volume in cerebral blood (Dai et al., 2003), $V_{b,\text{brain}}$ is calculated by:

$$V_{b,\text{brain}} = \frac{BW \times 0.014}{1 - Hct}$$

(Equation 3)

where BW and Hct are the brain weight and the hematocrit, respectively. By rearranging the equation 2, the $A_{b,\text{brain}}$ can be calculated by using the following equation:
\[ A_{b,\text{brain}} = R_b \times A_{p,\text{brain}} \times \frac{V_{b,\text{brain}}}{V_{p,\text{brain}}} = R_b \times \frac{BW \times 0.014}{1 - Hct} \times C_p \text{ (Equation 4)} \]

where \( C_p \) is the systemic plasma concentration.

The hematocrit (Hct) was estimated to be 0.45 (Bolliger and Everds, 2012). Brain concentrations were calculated by subtracting \( A_{b,\text{brain}} \) from the drug amount in brain homogenate and then, the drug amount in the brain tissue, that does not include the amount of drug in the blood of that tissue, was divided by the brain weight. This method yields the concentration that represents the exposure of the brain tissue to the drug. The spinal cord tissue was evaluated in the same manner.

**Pharmacokinetic calculation**

Plasma and tissue concentration-time profiles of alisertib after intravenous administration were analyzed using the non-compartmental analysis (NCA) module of Phoenix WinNonlin version 8.3 (Certara USA, INC., Princeton, NJ). The terminal rate constant was determined by linear regression using at least 3 data points in the terminal phase. The pharmacokinetic parameters and metrics, including area under the curve (AUC), clearance, volume of distribution, terminal elimination rate constant, and half-life, reported by Phoenix NCA are presented in Table 2.

The tissue-to-plasma partition coefficient (Kp) was calculated by the ratio of AUC_{inf} of each tissue to AUC_{inf} of plasma. The tissue-to-plasma concentration ratios at 0.25 and 1 hour after administration were calculated by the ratio of the tissue concentration at 0.25 and 1 hour to the plasma concentration at the corresponding time. The tissue-to-plasma partition coefficient of free drug (Kp_{free}) was calculated by multiplying the Kp with the ratio of free fraction of alisertib in tissue to free fraction of alisertib in plasma. Distribution advantage was calculated by dividing Kp of \textit{Mdr1a/b}^{−/−} \textit{Bcrp1}^{−/−} mice by Kp of wild-type mice in each brain region, the spinal cord, and the bone marrow.

**Statistical analysis**
All experimental data are presented as mean ± standard deviation except for the AUC\textsubscript{last} which is presented as mean ± standard error calculated by Bailer’s method using the Phoenix NCA module (Bailer, 1988). The standard deviation of AUC\textsubscript{inf} was calculated using Yuan’s method as previously reported (Yuan, 1993). A standard deviation of the blood-to-plasma ratio was calculated using propagation of error.

An unpaired t-test was performed to compare protein binding between concentrations and between matrices. The plasma and brain data collected from 4 genotypes after 1 hour of administration were analyzed by One-way ANOVA and Two-way ANOVA followed by Tukey’s post hoc test, respectively.

Data from co-administration study with elacridar were compared by Two-way ANOVA followed by Tukey’s post hoc test. Normal distribution of data was confirmed with the Shapiro-Wilk test. All statistical comparisons were performed using GraphPad Prism 9.1.1 (GraphPad Software, La Jolla, CA).
Results

Protein binding and blood-to-plasma ratio

Free fractions of alisertib in plasma, brain, and spinal cord are shown in Table 1. Plasma free fraction of alisertib is approximately 7-fold higher than free fractions in the brain and spinal cord. Binding of alisertib to the brain was similar as in the spinal cord with no statistical difference between brain and spinal cord at both 2 and 10 µM (p > 0.05). At 2 µM, free fraction of alisertib was greater when compared to 10 µM in plasma and brain, and the difference was about 1.2-fold (p < 0.05). Alisertib was stable in plasma, brain homogenate, and spinal cord homogenate for 24 hours at 37°C. The concentrations after a 24 hour-incubation were 90 – 113% compared to the concentrations in each matrix at time zero (data not shown). The average of free fraction for each matrix (4.2 ± 0.7%, 0.63 ± 0.09%, and 0.61 ± 0.10% in plasma, brain, and spinal cord, respectively) was used to calculate Kp,uu.

The blood-to-plasma ratio of alisertib was 0.76 ± 0.05 and 0.78 ± 0.08 at 1 and 10 µM with 5 replicates, respectively, and was not statistically different with respective to concentration (p > 0.05). The average, 0.77, was used to correct alisertib concentrations in residual tissue blood.

Systemic exposure and CNS distribution of alisertib in wild-type and Mdr1a/b−/−Bcrp1−/− mice

The concentration-time profiles of plasma, 6-brain regions, and spinal cord in wild-type and Mdr1a/b−/−Bcrp1−/− mice resulting from intravenous administration of alisertib at 5 mg/kg are depicted in Figures 1 and 2. The plasma concentrations declined in a biexponential manner in wild-type mice and the similar concentration-time profiles were observed in Mdr1a/b−/−Bcrp1−/− mice with very similar terminal elimination rate constants (0.17 hr⁻¹ and 0.14 hr⁻¹ in wild-type and Mdr1a/b−/−Bcrp1−/− mice, respectively). The sampling design was adequate to determine the AUCₐₗₙₜ for plasma, brain, and spinal cord, where the extrapolated AUC% was 0.49 – 2.4%. Clearance, volume of distribution, and terminal half-life were similar between wild-type and Mdr1a/b−/−Bcrp1−/− mice (Table 2).
Concentrations of alisertib in the brain and spinal cord at 24 hour-post dose in wild-type mice were below the LOQ or not detected except for the concentration in medulla which was pooled for the analysis because the specimen from each mouse was limiting. The brain concentration of alisertib was corrected by subtracting alisertib concentrations in residual cerebral blood as described in the Materials and Methods section. The concentration-time profiles and the \( K_p \)-time profiles of alisertib in 6-anatomical brain regions and the spinal cord were superimposable in wild-type and \( Mdr1a/b-/-Bcrp1-/- \) mice (Figure 1-4). \( K_{p,\text{brain}} \) and \( K_{p,\text{spinal cord}} \) rapidly increased, peaking at 1 hour after administration and then decreased, reaching a plateau after approximately 8 hours. In mice lacking P-gp and Bcrp, CNS concentrations and \( K_p \) of alisertib were significantly greater compared to those in wild-type mice for the duration of the sampling period and the distribution advantage, i.e., the ratio of unbound CNS-to-plasma partition coefficient, in \( Mdr1a/b-/-Bcrp1-/- \) mice to that in wild-type mice, was approximately 6 (Figure 1-4, Table 3). These results suggest that alisertib is a substrate of P-gp and/or Bcrp, leading us to examine whether alisertib is a single substrate for either transporter, or a dual substrate for both, using \( Mdr1a/b-/- \) and \( Bcrp1-/- \) mice.

The brain-to-plasma partition coefficients ranged from 0.024 to 0.037 across the brain regions and was 0.020 for spinal cord in wild-type mice, consistent with a previous report (Sells et al., 2015). However, considering the free drug hypothesis that only free drug concentration exerts pharmacological activity (Smith et al., 2010), \( K_{p,\text{uu}} \), an unbound tissue-to-plasma partition coefficient, and the free concentration in the brain, should be utilized to associate drug distribution into the CNS with therapeutic outcome. The \( K_{p,\text{uu}} \), which is the corrected \( K_p \) using the free fraction of alisertib in plasma and tissue, decreased by 7-fold compared to \( K_p \), in wild-type mice (0.0036 – 0.0055 and 0.0028 for the brain regions and spinal cord, respectively), indicating that the distribution into the brain from the blood of pharmacologically available alisertib is low (Table 3).

**Regional CNS distribution of alisertib**
Distribution of alisertib into 6-anatomical brain regions and spinal cord was similar by comparing AUC\textsubscript{tissue}, K\textsubscript{p}, and K\textsubscript{p,uu} in wild-type and M\textsubscript{dr1a/b-/-}\textsubscript{Bcrp1-/-} mice (Table 2 and 3). Because the CNS regions from wild-type and M\textsubscript{dr1a/b-/-}\textsubscript{Bcrp1-/-} mice were collected by destructive sampling, we statistically compared the regional distribution of alisertib in wild-type, M\textsubscript{dr1a/b-/-}, Bcrp1-/-, and M\textsubscript{dr1a/b-/-Bcrp1-/-} mice after 1 hour-post intravenous administration. The T\textsubscript{max} of the tissue-to-plasma concentration ratio, which occurred at one hour-post dose, was chosen as the time point to ascertain the difference in regional distribution amongst the 4 mouse genotypes. The tissue concentrations and the tissue-to-plasma concentration ratios were not statistically different across the CNS regions in each genotype (Figure 5B and Table 4). The p values were 0.7210 and 0.1372 when the tissue concentrations and the tissue-to-plasma concentration ratios, respectively, were compared between brain regions by Two-way ANOVA and no significant pair was observed within the same genotype.

**Influence of P-gp and Bcrp on CNS distribution of alisertib**

The results in wild-type and M\textsubscript{dr1a/b-/-}\textsubscript{Bcrp1-/-} mice suggest that alisertib is a substrate of P-gp and/or Bcrp. To examine if alisertib is a single or dual substrate of efflux transporters, a mouse lacking only P-gp or Bcrp was employed. One hour after intravenous bolus administration, no difference in plasma concentrations of alisertib was observed amongst four genotypes except for M\textsubscript{dr1a/b-/-} mice compared to wild-type mice with approximately a 1.3-fold difference (Figure 5A). The CNS concentrations in M\textsubscript{dr1a/b-/-} and M\textsubscript{dr1a/b-/-\textsubscript{Bcrp1-/-}} mice were about 8-fold higher compared to those in wild-type and Bcrp1-/- mice and the effect of genotype on the CNS concentration of alisertib was significant (p < 0.001) (Figure 5B). When compared the same CNS region between genotypes, the tissue-to-plasma concentration ratios were significantly higher in M\textsubscript{dr1a/b-/-} and M\textsubscript{dr1a/b-/-\textsubscript{Bcrp1-/-}} mice compared to wild-type mice; approximately 5- and 6-fold, respectively (p < 0.001 for all comparisons). On the contrary, the lack of Bcrp did not affect CNS distribution of alisertib where the tissue-to-plasma concentration ratio was similar between wild-type and Bcrp1-/- mice, and between M\textsubscript{dr1a/b-/-} and M\textsubscript{dr1a/b-/-\textsubscript{Bcrp1-/-}} mice (Table 4). These *in vivo* results in the CNS suggest that alisertib is a substrate of P-gp, but not a substrate.
of Bcrp. Given the results in the 4 genotypes of mice, we conclude that there is no Bcrp influence on CNS distribution of alisertib since there is no compensation between Bcrp and P-gp (Chen et al., 2009; Kodaira et al., 2010; Agarwal, Hartz, et al., 2011).

**Elacridar, an inhibitor of P-gp and Bcrp, influences CNS distribution of alisertib**

Elacridar is a potent dual inhibitor of P-gp and Bcrp (Hyafil et al., 1993; Allen et al., 1999; Sane, Agarwal, et al., 2013). We examined the effect of this pharmacological inhibitor on CNS distribution of alisertib after co-dosing with alisertib in wild-type and Mdr1a/b−/− Bcrp1−/− mice. Plasma concentrations of alisertib at 0.25 hour-post dose were similar regardless of genotype and elacridar treatment. At 1 hour-post dose, plasma concentrations of alisertib of the vehicle-treated group were 1.6-fold higher in Mdr1a/b−/− Bcrp1−/− mice compared to wild-type mice, although they were similar between wild-type and Mdr1a/b−/− Bcrp1−/− mice that did not receive the vehicle (Figure 5A and 6D). It is doubtful that the vehicle of elacridar affected systemic exposure of alisertib, but currently, the reason for this difference is not clear.

The inhibitory effect of elacridar on brain and spinal cord distribution of alisertib was absent at 0.25 hour-post dose (Figure 6B-C). In wild-type mice, brain and spinal cord distribution of alisertib was markedly increased in the elacridar-treated group compared to the vehicle-treated group after 1 hour of administration, indicating that CNS distribution of alisertib was improved due to inhibition of efflux of alisertib by elacridar treatment (Figure 6E-F and Table 5). In Mdr1a/b−/− Bcrp1−/− mice, CNS distribution of alisertib was not different between the vehicle- and elacridar-treated groups (p = 0.9995 and 0.9797 for brain and spinal cord, respectively, at 1 hour-post dose), suggesting that elacridar was not able to exhibit inhibitory effect due to lack of P-gp.

**Bone marrow distribution**

Distribution of alisertib into bone marrow in wild-type and Mdr1a/b−/− Bcrp1−/− mice was determined following a single intravenous administration of alisertib at 5 mg/kg to determine if the concentrations at the site of toxicity are associated with function of P-gp and/or Bcrp. The alisertib concentration time-
profiles in bone marrow were very similar to those in plasma with the bone marrow concentrations 3 – 4 times lower than the plasma concentration in wild-type and Mdr1a/b⁻/⁻ Bcrp1⁻/⁻ mice. The elimination rate constants were almost identical between plasma and bone marrow in both genotypes (Figure 7 and Table 2). Interestingly, alisertib distributed into bone marrow rapidly and the bone marrow-to-plasma concentration ratio reached a plateau within 5 minutes after intravenous administration. Kₚ of bone marrow was 0.30 and 0.25 in wild-type and Mdr1a/b⁻/⁻ Bcrp1⁻/⁻ mice, respectively, and the bone marrow-to-plasma concentration ratios were also similar in all genotypes after 1 hour of intravenous administration (Table 3 and 4). Because the amount of bone marrow collected was limiting, the free fraction in bone marrow was not able to be determined and subsequently Kₚ,uu was not calculated.
Discussion

Chemotherapy is a necessary component in the treatment of most malignant brain tumors, especially when the tumor is not amenable to surgical resection and may be resistant to radiotherapy. A critical determinant of the efficacious use of chemotherapy in this context is adequate drug distribution through a heterogeneously intact BBB. Drug delivery leading to efficacy is dependent upon: 1) BBB permeability (including influence of active efflux transport), 2) drug binding in the brain and at the tumor site, and 3) a sufficient retention time, in light of the drug’s mechanism of cell kill, at the site of action. Moreover, understanding the relative exposures to sites of action versus sites of toxicity is critical in developing specific dosage regimens with an acceptable therapeutic index. A full appreciation of these parameters for specific drugs in certain types of brain tumor is required for informed clinical trial design.

Efflux transport systems influence drug distribution even in the brain tumor core (de Gooijer et al., 2021; Griffith et al., 2021). We evaluated the brain and spinal cord distribution of alisertib in wild-type and transporter-knockout mice, and these in vivo results show that alisertib is a substrate of P-gp and not Bcrp. Alisertib has a limited CNS penetration in the mouse due in large part to the efflux mediated by P-gp. Importantly for the use of alisertib in brain tumors, its distribution was consistently uniform in different anatomical regions of the brain. This finding also implies an equivalent functional activity of P-gp throughout the different anatomical regions.

Some brain tumors occur in specific brain regions, for example, diffuse midline gliomas in the brainstem/thalamus while medulloblastomas normally occur around the 4th ventricle. Both are tumor types that are under study for treatment with alisertib (Hill et al., 2015; Zhang et al., 2018). Alisertib is also in a phase 2 study for patients with atypical teratoid rhabdoid tumors (NCT02114229). In this sense, we evaluated CNS distribution of alisertib in 6-anatomical brain regions (cortex, cerebellum, thalamus and hypothalamus, pons, midbrain, and medulla) and the spinal cord with respect to the function of efflux transporters. $K_p$ and $K_{pu}$ of alisertib was consistent across these regions in wild-type mice, suggesting that alisertib distributes uniformly throughout the CNS regions. Moreover, a uniform increase of $K_p$ in
mice lacking P-gp implies that there is no functional difference in P-gp activity from one CNS region to another. This finding is in line with a previous report where the brain distribution of colchicine, a P-gp substrate, did not match in different brain areas after *in situ* brain perfusion, but it was correlated to the regional flow rate of perfusate. Importantly, the brain distribution of colchicine was significantly increased, in all brain regions studied, by including PSC833 or elacridar in the perfusate (Youdim *et al.*, 2004). Also, positron emission tomography scans of verapamil and *N*-desmethyl-loperamide, which are typical substrates of P-gp, in the brain in a human and a non-human primate, respectively, showed a uniform function of P-gp across different brain regions (Liow *et al.*, 2009; Eyal *et al.*, 2010). The other reason for uniform distribution of alisertib in the brain could be explained by the uniform expression of P-gp in various mouse brain regions. mRNA and protein abundance of P-gp measured in the homogenates of cortex, striatum, midbrain, and hippocampus were similar (You *et al.*, 2019). However, considering P-gp exists in the cerebral endothelium, the region-specific expression determined from isolated brain microvessels could be performed for a more precise interpretation.

In addition to the activity and expression of efflux transporters, other contributors affecting the CNS distribution of some drugs include the cerebral blood flow to different brain areas as described above for colchicine distribution. Differences of regional distribution of flavonoids and steroids were also associated with regional flow in the brain (Youdim *et al.*, 2004; Chugh *et al.*, 2009; Qaiser *et al.*, 2017). The uniform distribution of alisertib in wild-type mice, the uniform increase in distribution in *Mdr1a/b<sup>−/−</sup>* and *Mdr1a/b<sup>−/−</sup>Bcrp1<sup>−/−</sup>* mice, and the similar distribution between wild-type and *Bcrp1<sup>−/−</sup>* mice indicate alisertib brain distribution is permeability rate limited with P-gp-mediated efflux at the BBB a major determinant of distribution from blood to the brain.

In addition to the BBB penetrability, variable tissue composition, such as in lipids and proteins, could be another factor that determines distribution of active drug in CNS areas. The lipid content varies between brain regions in rodents with the highest in the medulla and the lowest in the cortex (Chavko *et al.*, 1993). In humans, the lipid composition is different between brain regions and also between different age groups.
Given that the content of phospholipids and neutral lipid affected intracellular drug bioavailability by influencing free drug concentrations and lysosomal pH, respectively, in *in vitro* experiments, lipid composition and content could be predicted to affect the regional exposure to drugs in the CNS (Treyer *et al*., 2018). Considering the high lipophilicity of alisertib ($\log P = 5$), it could be postulated that the brain distribution of alisertib is affected by different lipid compositions and contents across the brain regions. However, lipid binding of alisertib is currently unknown. Although $K_{puw}$ of alisertib was similar in different CNS regions in mice, it is worthwhile to take lipid binding into account to predict the free drug concentration of alisertib in human brain or tumor tissues. As for the protein composition, it is known that tight junction proteins are more expressed in the white matter than the grey matter (Nyúl-Tóth *et al*., 2016). In light of the primary function of the tight junction expressed in CNS, the entry of drugs into the white matter regions would be more restricted than that into the grey matter regions (Daniel *et al*., 2001). In this study, we did not distinguish the grey and white matter when dissecting the CNS regions, so it is difficult to compare the effect of the expression of tight junctional proteins on CNS distribution of alisertib. Nevertheless, our results inform that alisertib is available evenly in whole brain regions and spinal cord.

P-gp and Bcrp are the major efflux transporters expressed in the CNS. Thus, determining if a drug candidate targeting CNS disease is a substrate of P-gp and Bcrp is essential in the drug development process (Agarwal, Sane, *et al*., 2011). Previously, Michaelis *et al*. investigated whether P-gp and BCRP was involved in transporting alisertib into neuroblastoma cells by measuring the $IC_{50}$ with the MTT assay. That study indicated that alisertib is not exported by P-gp nor BCRP, however their interpretation of the results for P-gp needs clarification. Indeed, the results showed that the $IC_{50}$ of alisertib is not significantly changed with high expression of ABCB1, encoding P-gp in humans (Michaelis *et al*., 2014, 2015). In contrast, our results in wild-type and transporter knockout mice suggest that alisertib is a substrate of P-gp, but not of Bcrp. These results are supported by the previous report that suggests alisertib is a P-gp substrate, not only by comparing accumulation of alisertib in Caco-2 cells in presence and absence of
verapamil, but also by showing higher brain uptake of $[^{11}C]$-alisertib in P-gp knockout mice compared to wild-type mice (Goos et al., 2016). Recently, it was demonstrated that alisertib was transported by ABCB1 by the bidirectional study in a MDCKII-ABCB1 transfected cell line (Vagiannis et al., 2022).

As Figure 1 and 2 show, the plasma concentration-time profile of alisertib is superimposable between wild-type and $Mdr1a/b^{-/-}Bcrp1^{-/-}$ mice. These results indicate that the transport systems are likely not impacting the systemic clearance of alisertib. In rodents, alisertib is metabolized by glucuronidation, hydroxylation, and oxidation with a moderate hepatic extraction ratio across species (Yang et al., 2014). Also, in humans, approximately 90% of orally dosed alisertib was excreted through the fecal route, with approximately 26% of the unchanged drug excreted in the feces, and the urinary excretion was minimal (Pusalkar et al., 2020). These reports suggest that the major pathway of elimination is metabolism rather than excretion/secretion, indicating that the effect of transport by P-gp on the systemic exposure of alisertib would not be significant.

The inhibitory effect of elacridar on CNS distribution of alisertib was not observed after 0.25 hours post co-administration of alisertib and elacridar in wild-type mice. However, it was clearly shown to increase inhibitory effect after 1 hour post administration (Figure 6, Table 5). The $t_{\text{max}}$ of elacridar in plasma is 1 hour after intraperitoneal injection. Considering that free plasma concentrations of elacridar are approximately 0.03 and 0.2 µM after 0.25 and 1 hour of intraperitoneal injection, respectively, the pharmacologically active concentration of elacridar may not be high enough to inhibit export of alisertib from the CNS after 0.25 hours post dose (Kallem et al., 2012; Sane, Mittapalli, et al., 2013). The inhibitory potential of elacridar against efflux by P-gp varies depending upon the substrate, but to our knowledge, neither the IC$_{50}$ nor the K$_i$ of elacridar to inhibit the transport of alisertib by P-gp is known (Tang et al., 2002; Rautio et al., 2006).

Adverse events are one of the major determinants for the clinical application of investigational drugs. Therefore, the drug distribution into the site of toxicity as well as into the site of efficacy is necessary information to inform an appropriate dosage regimen that will optimize the therapeutic index in patients.
One of the dose-limiting side effects of alisertib is myelosuppression. This has been observed with a high frequency where more than 40% of 249 patients experienced grade 3-4 myelosuppression during a phase II clinical trial (Melichar et al., 2015). The toxicity of alisertib was dose-related with a higher frequency in children than in adults (Dees et al., 2012; Mossé et al., 2012; Melichar et al., 2015; Lin et al., 2016). In this preclinical study, bone marrow concentrations of alisertib were comparable to plasma concentrations which were similar in wild-type and P-gp knockout mice. Although it is known that P-gp exerts a barrier function in hematopoietic cells (Schinkel et al., 1997), its relative expression and function in bone marrow cells compared to the epithelium in the CNS is unclear. Moreover, free concentrations of alisertib in bone marrow were not available. Despite of these limitations, our results, i.e., similar bone marrow $K_p$ in wild-type and transgenic mice lacking P-gp, indicate that P-gp does not play a significant role in the bone marrow distribution of alisertib. Also, considering the similar pharmacokinetic profiles and comparable concentrations between bone marrow and plasma as shown in Figure 7, the bone marrow concentrations of alisertib are predictable from plasma concentrations, allowing one to use the relationship between the systemic exposure and myelosuppression to help guide dosing.

Alisertib exhibited a promising therapeutic effect in glioblastoma cell lines with an IC$_{50}$ in the range of 30 – 95 nM, the equivalent of 16 – 49 ng/mL (Kurokawa et al., 2017). If alisertib is administered systemically, and given the $K_{pu}$ we determined in the brain, the plasma concentrations of alisertib need to be at least 86 µg/mL to achieve an efficacious concentration in the brain. The human equivalent dose for 30 mg/kg in mice, one that improved survival in orthotopic glioblastoma models, is estimated to be approximately 170 mg/70 kg (Nair and Jacob, 2016). In patients, however, $C_{max}$ of alisertib was approximately 2 µg/mL after a single oral dose of 150 mg and approximately 1.7 µg/mL after 50 mg of twice daily doses for 7 days (Dees et al., 2012), suggesting that a much higher dose than the clinical dose currently employed is required to reach the effective concentration for the treatment of CNS tumors. However, given that this high systemic exposure would result in a higher risk of side effects, especially myelosuppression, this dose is not clinically feasible. An alternative to a high systemic dose is a direct
delivery method into the CNS that bypasses the BBB, such as convection-enhanced delivery (CED). This could be adopted to avoid high systemic exposure while maximizing availability of alisertib at the disease site. Importantly, if CED is to be utilized, the impact of active efflux on the mean transit time of alisertib at the tumor site needs to also be considered. This may result in either multiple or longer duration administration by CED.

In conclusion, we have shown that the CNS penetration of alisertib is limited with an equivalent distribution across several anatomical regions in the mouse CNS. Also, this study shows that P-gp, rather than Bcrp, plays a significant role in restricting CNS distribution of alisertib, and the influence of P-gp on brain distribution, as measured by the brain-to-plasma concentration ratio is uniform throughout the CNS regions studied. Moreover, to our knowledge, this is the first report to quantitatively determine the bone marrow distribution of alisertib over time. The concentration of alisertib in bone marrow rapidly becomes proportional to that in plasma. The bone marrow concentration is significantly higher than the CNS concentration, indicating that systemic exposure of alisertib may cause adverse events related to bone marrow suppression when treating patients with CNS tumors. Taken together, distribution of alisertib is low at the site of efficacy, the CNS, but high at the site of toxicity, the bone marrow in mice. These results warrant further investigation to secure an efficacious concentration in the CNS with low systemic exposure. Targeted delivery to the CNS (Figure 8) could be utilized for this purpose.
Acknowledgments

The authors thank James Fisher (Clinical Pharmacology Analytical Services Laboratory, University of Minnesota) and Yingchun Zhao (Analytical Biochemistry, Masonic Cancer Center, University of Minnesota) for their help and support in the development and optimization of the LC-MS/MS analysis.

Authorship contributions

Participated in research design: Oh, Elmquist, Power, Daniels

Conducted experiments: Oh, Zhang

Performed data analysis: Oh, Elmquist

Wrote or contributed to the writing of the manuscript: Oh, Elmquist
Reference


Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.


Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat. *J Neurochem* **142**:672–685.


Financial Disclosure

No author has an actual or perceived conflict of interest with the contents of this article.

Footnotes

This work was supported by the State of Minnesota [Minnesota-Mayo Partnership grant ML2020], the National Institutes of Health [Grants U01 CA227954 and U54 CA210181], and National Institutes of Health (NIH)-National Cancer Institute (NCI) [Grant U19 CA264362]. E.A.P. would like to acknowledge that this publication was supported by CTSA Grant Number TL1 TR002380 from the National Center for Advancing Translational Science (NCATS).
**Figure Legends**

Figure 1. Plasma and tissue concentration-time profile of alisertib after a single intravenous dose of 5 mg/kg in wild-type mice. The tissue concentration of alisertib was corrected by subtracting alisertib concentrations in residual tissue blood as described in the Materials and Methods section. Data represent mean ± SD (n=4 at each time point except for medulla. Medulla collected from 4 mice was pooled, and then subjected to analysis).

Figure 2. Plasma and tissue concentration-time profile of alisertib after a single intravenous dose of 5 mg/kg in *Mdr1a/b<sup>−/−</sup>Bcrp1<sup>−/−</sup>* mice. The tissue concentration of alisertib was corrected by subtracting alisertib concentrations in residual tissue blood as described in the Materials and Methods section. Data represent mean ± SD (n=4 at each time point except for medulla. Medulla collected from 4 mice was pooled, and then subjected to analysis).

Figure 3. Tissue-to-plasma concentration ratio-time profile of alisertib after a single intravenous dose of 5 mg/kg in wild-type mice. Data represent mean ± SD (n=4 at each time point except for medulla. Medulla collected from 4 mice was pooled, and then subjected to analysis).

Figure 4. Tissue-to-plasma concentration ratio-time profile of alisertib after a single intravenous dose of 5 mg/kg in *Mdr1a/b<sup>−/−</sup>Bcrp1<sup>−/−</sup>* mice. Data represent mean ± SD (n=4 at each time point except for medulla. Medulla collected from 4 mice was pooled, and then subjected to analysis).

Figure 5. Alisertib concentrations in plasma (A), CNS (B), and bone marrow (C) at 1 hour-post dose following a single intravenous injection of 5 mg/kg in wild-type, *Mdr1a/b<sup>−/−</sup>, Bcrp1<sup>−/−</sup>,* and *Mdr1a/b<sup>−/−</sup>*
Bcrp1−/− mice. The tissue concentration of alisertib was corrected by subtracting alisertib concentrations in residual tissue blood as described in the Materials and Methods section. *, *p < 0.05 compared with wild-type mice using One-way ANOVA followed by Tukey’s post hoc test. Data represent mean ± SD (n=4 at each time point except for medulla. Medulla collected from 4 mice was pooled, and then subjected to analysis).

Figure 6. Alisertib concentrations in plasma (A and D), brain (B and E), and spinal cord (C and F) at 0.25 hour- (A, B, and C) and 1 hour-post dose (D, E, and F) following co-administration of a single intravenous dose of alisertib (5 mg/kg) and a single intraperitoneal dose of elacridar (10 mg/kg) in wild-type and Mdr1a/b−/− Bcrp1−/− mice. The closed and open bar represent the vehicle- and elacridar-treated group, respectively. The tissue concentration of alisertib was corrected by subtracting alisertib concentrations in residual tissue blood as described in the Materials and Methods section. *, *p < 0.05 and ***, *p < 0.001 compared with the corresponding wild-type mice. ###, *p < 0.001 compared with the corresponding vehicle-treated group. Statistical analysis was performed by Two-way ANOVA followed by Tukey’s post hoc test. Data represent mean ± SD (n=4).

Figure 7. Plasma and bone marrow concentration-time profiles of alisertib after a single intravenous dose of 5 mg/kg in wild-type (A) and Mdr1a/b−/− Bcrp1−/− mice (B), and bone marrow-to-plasma concentration ratio-time profile (C). Plasma concentrations are the same as in the Figures 1 and 2. Data represent mean ± SD (n=4 at each time point).

Figure 8. Predicted exposure profiles of alisertib, efficacy, and toxicity in treatment of CNS tumors following direct and systemic delivery of alisertib.
Tables

Table 1. Protein binding of alisertib in plasma, brain, and spinal cord.

<table>
<thead>
<tr>
<th></th>
<th>% unbound</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plasma</td>
<td>Brain</td>
<td>Spinal cord</td>
</tr>
<tr>
<td>2 µM</td>
<td>4.7 ± 0.7</td>
<td>0.69 ± 0.04</td>
<td>0.64 ± 0.13</td>
</tr>
<tr>
<td>10 µM</td>
<td>3.8 ± 0.3*</td>
<td>0.57 ± 0.07*</td>
<td>0.58 ± 0.04</td>
</tr>
</tbody>
</table>

Data represent mean ± SD (n=5).

*, p < 0.05 compared with 2 µM of the corresponding matrix.
Table 2. Pharmacokinetic parameters of alisertib following a single intravenous dose of 5 mg/kg in wild-type and *Mdr1a/b<sup>−/−</sup> Bcrp1<sup>−/−</sup>* mice.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>AUC&lt;sub&gt;last&lt;/sub&gt; (μg·hr/mL)</th>
<th>AUC&lt;sub&gt;inf&lt;/sub&gt; (μg·hr/mL)</th>
<th>CL (mL/hr/kg)</th>
<th>V&lt;sub&gt;ss&lt;/sub&gt; (mL/kg)</th>
<th>K&lt;sub&gt;e&lt;/sub&gt; (hr&lt;sup&gt;−1&lt;/sup&gt;)</th>
<th>T&lt;sub&gt;1/2&lt;/sub&gt; (hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>12 ± 0</td>
<td>12 ± 0</td>
<td>404</td>
<td>925</td>
<td>0.17</td>
<td>4.2</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>14 ± 1</td>
<td>14 ± 1</td>
<td>348</td>
<td>1181</td>
<td>0.14</td>
<td>5.1</td>
</tr>
<tr>
<td>Cortex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.36 ± 0.02</td>
<td>0.36 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.24</td>
<td>2.9</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.4 ± 0.2</td>
<td>2.4 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.16</td>
<td>4.4</td>
</tr>
<tr>
<td>Cerebellum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.42 ± 0.02</td>
<td>0.43 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.19</td>
<td>3.7</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.8 ± 0.2</td>
<td>2.8 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.16</td>
<td>4.3</td>
</tr>
<tr>
<td>Thalamus + Hypothalamus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.32 ± 0.02</td>
<td>0.33 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.20</td>
<td>3.4</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.4 ± 0.2</td>
<td>2.4 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.17</td>
<td>4.1</td>
</tr>
<tr>
<td>Pons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.46 ± 0.02</td>
<td>0.46 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.23</td>
<td>3.0</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.9 ± 0.2</td>
<td>2.9 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.18</td>
<td>3.9</td>
</tr>
<tr>
<td>Midbrain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.29 ± 0.02</td>
<td>0.30 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.14</td>
<td>4.8</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.4 ± 0.2</td>
<td>2.4 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.17</td>
<td>4.0</td>
</tr>
<tr>
<td>Medulla&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.34</td>
<td>0.34</td>
<td>-</td>
<td>-</td>
<td>0.14</td>
<td>5.0</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.3</td>
<td>2.4</td>
<td>-</td>
<td>-</td>
<td>0.16</td>
<td>4.2</td>
</tr>
<tr>
<td>Spinal cord</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>0.24 ± 0.02</td>
<td>0.24 ± 0.02</td>
<td>-</td>
<td>-</td>
<td>0.18</td>
<td>3.7</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>2.7 ± 0.2</td>
<td>2.8 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.17</td>
<td>4.2</td>
</tr>
<tr>
<td>Bone marrow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>3.7 ± 0.1</td>
<td>3.7 ± 0.1</td>
<td>-</td>
<td>-</td>
<td>0.17</td>
<td>4.2</td>
</tr>
<tr>
<td><em>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt; Bcrp1&lt;sup&gt;−/−&lt;/sup&gt;</em></td>
<td>3.6 ± 0.2</td>
<td>3.7 ± 0.2</td>
<td>-</td>
<td>-</td>
<td>0.13</td>
<td>5.2</td>
</tr>
</tbody>
</table>

Data represent mean ± SE and mean ± SD for AUC<sub>0-last</sub> and AUC<sub>inf</sub>, respectively (n=4 at each time point).

<sup>a</sup> Medulla collected from 4 mice at each time point was pooled, and then subjected to analysis.

AUC<sub>last</sub>, area under the curve from time zero to the last sampling time point; AUC<sub>inf</sub>, area under the curve from time zero to infinity; CL, clearance; V<sub>ss</sub>, volume of distribution at steady state; K<sub>e</sub>, terminal elimination rate constant; T<sub>1/2</sub>, half-life.
Table 3. Tissue-to-plasma partition coefficient of alisertib following a single administration of 5 mg/kg in wild-type and Mdr1a/b−/− Bcrp1−/− mice.

<table>
<thead>
<tr>
<th></th>
<th>Wild-type</th>
<th></th>
<th>Mdr1a/b−/− Bcrp1−/−</th>
<th></th>
<th>Distribution advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K_p</td>
<td>K_p,uu</td>
<td>K_p</td>
<td>K_p,uu</td>
<td></td>
</tr>
<tr>
<td>Cortex</td>
<td>0.029</td>
<td>0.0043</td>
<td>0.17</td>
<td>0.025</td>
<td>5.79</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.035</td>
<td>0.0052</td>
<td>0.20</td>
<td>0.029</td>
<td>5.63</td>
</tr>
<tr>
<td>Thalamus + Hypothalamus</td>
<td>0.026</td>
<td>0.0039</td>
<td>0.17</td>
<td>0.025</td>
<td>6.46</td>
</tr>
<tr>
<td>Pons</td>
<td>0.037</td>
<td>0.0055</td>
<td>0.20</td>
<td>0.030</td>
<td>5.39</td>
</tr>
<tr>
<td>Midbrain</td>
<td>0.024</td>
<td>0.0036</td>
<td>0.17</td>
<td>0.025</td>
<td>6.99</td>
</tr>
<tr>
<td>Medulla</td>
<td>0.028</td>
<td>0.0041</td>
<td>0.16</td>
<td>0.024</td>
<td>5.90</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>0.020</td>
<td>0.0028</td>
<td>0.19</td>
<td>0.028</td>
<td>9.79</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>0.30</td>
<td>-</td>
<td>0.25</td>
<td>-</td>
<td>0.84</td>
</tr>
</tbody>
</table>

K_p was calculated using AUC from time zero to infinity after destructive sampling from 4 mice at each time point.

* Medulla collected from 4 mice at each time point was pooled, and then subjected to analysis.

K_p, tissue-to-plasma partition coefficient; K_p,uu, unbound tissue-to-plasma partition coefficient.
Table 4. Tissue-to-plasma concentration ratio of alisertib at 1 hour-post dose following a single intravenous administration of 5 mg/kg in wild-type, Mdr1a/b−/−, Bcrp1−/−, and Mdr1a/b−/− Bcrp1−/− mice.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Wild-type</th>
<th>Mdr1a/b−/−</th>
<th>Bcrp1−/−</th>
<th>Mdr1a/b−/− Bcrp1−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortex</td>
<td>0.045 ± 0.006</td>
<td>0.20 ± 0.03***</td>
<td>0.031 ± 0.001</td>
<td>0.26 ± 0.04***</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.052 ± 0.011</td>
<td>0.20 ± 0.03***</td>
<td>0.038 ± 0.005</td>
<td>0.28 ± 0.04***</td>
</tr>
<tr>
<td>Thalamus +</td>
<td>0.040 ± 0.009</td>
<td>0.20 ± 0.05***</td>
<td>0.033 ± 0.009</td>
<td>0.26 ± 0.04***</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pons</td>
<td>0.054 ± 0.006</td>
<td>0.22 ± 0.04***</td>
<td>0.043 ± 0.011</td>
<td>0.30 ± 0.05***</td>
</tr>
<tr>
<td>Midbrain</td>
<td>0.037 ± 0.008</td>
<td>0.20 ± 0.03***</td>
<td>0.028 ± 0.004</td>
<td>0.27 ± 0.04***</td>
</tr>
<tr>
<td>Medulla a</td>
<td>0.039</td>
<td>0.18</td>
<td>0.039</td>
<td>0.25</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>0.035 ± 0.008</td>
<td>0.17 ± 0.03***</td>
<td>0.023 ± 0.002</td>
<td>0.29 ± 0.05***</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>0.34 ± 0.03</td>
<td>0.25 ± 0.04</td>
<td>0.26 ± 0.02</td>
<td>0.27 ± 0.06</td>
</tr>
</tbody>
</table>

Data represent mean ± SD (n=4).

a Medulla collected from 4 mice at each time point was pooled, and then subjected to analysis.

***, p < 0.001 compared with wild-type mice
Table 5. Tissue-to-plasma concentration ratio of alisertib at 0.25 hour- and 1 hour-post dose following co-administration of a single intravenous dose of alisertib (5 mg/kg) and a single intraperitoneal dose of elacridar (10 mg/kg) in wild-type and Mdr1a/b<sup>−/−</sup> Bcrp1<sup>−/−</sup> mice.

<table>
<thead>
<tr>
<th></th>
<th>Brain</th>
<th>Spinal cord</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle</td>
<td>Elacridar</td>
</tr>
<tr>
<td>Wild-type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.25 hr</td>
<td>0.046 ± 0.020</td>
<td>0.058 ± 0.005</td>
</tr>
<tr>
<td>1 hr</td>
<td>0.075 ± 0.016</td>
<td>0.27 ± 0.10&lt;sup&gt;##&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mdr1a/b&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.25 hr</td>
<td>0.21 ± 0.03**</td>
<td>0.24 ± 0.07***</td>
</tr>
<tr>
<td>1 hr</td>
<td>0.39 ± 0.07***</td>
<td>0.39 ± 0.01</td>
</tr>
</tbody>
</table>

Data represent mean ± SD (n=4).

* p < 0.05, ** p < 0.01, and *** p < 0.001 compared with the corresponding wild-type mice.

## p < 0.01 compared with the corresponding vehicle-treated group.
Figure 1.
Figure 2.

A graph showing the concentration of a substance in different tissues over time. The x-axis represents time in hours (0 to 25), and the y-axis represents concentration in ng/mL or ng/g tissue. The tissues include Plasma, Cortex, Cerebellum, Thalamus + Hypothalamus, Pons, Midbrain, Medulla, and Spinal cord. The data shows a decrease in concentration over time for all tissues, with some variability between different tissues.
Figure 3.
Figure 4.

Tissue-to-plasma concentration ratio vs. time (hr) for different brain regions: Cortex, Cerebellum, Thalamus + Hypothalamus, Pons, Midbrain, Medulla, and Spinal cord.
Figure 5.
Figure 6.
Figure 7.

A

Concentration (ng/mL or ng/g tissue)

Time (hr)

Plasma

Bone marrow

B

Concentration (ng/mL or ng/g tissue)

Time (hr)

Plasma

Bone marrow

C

Tissue-to-plasma concentration ratio

Time (hr)

Wild-type

Mdr1a/b<sup>−/−</sup> Bcrp1<sup>−/−</sup>
Figure 8.

**Direct delivery**

- **Plasma**
- **Brain**
- **Bone marrow**

**Systemic delivery**

- **Insufficient apoptosis of tumor cells with high toxicity**

**Graphs**

- **Efficacy** vs. **Toxicity**
  - Direct delivery:
    - Efficacy: Decreases over time
    - Toxicity: Increases over time
  - Systemic delivery:
    - Efficacy: Decreases over time
    - Toxicity: Increases over time